Reported 1 day ago
BMO Capital analyst Evan Seigerman has maintained a 'Hold' rating on Bristol-Myers Squibb (NYSE:BMY), with a price target set at $47.00. While the company has shown solid prescription growth for its product Cobenfy, it is expected to fall short of revenue expectations for Q3 2025, adding uncertainty to forecasts. The analyst suggests that despite BMY's potential, other AI stocks may offer better investment upside.
Source: YAHOO